NLRP3 and cryopyrin-associated periodic syndrome: MCC950 has been considered as the best-studied selective inhibitor of NLRP3 and is efficacious in a variety of immunopathological mouse models of NLRP3-driven diseases, such as CAPS, colitis, and steatohepatitis, but it was suspended in a phase II clinical trial for treating rheumatoid arthritis because of the hepatotoxicity (5).